ReviewJournal of cancer research and clinical oncology2023

A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma.

Xianghua Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.